Clinical Trial

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-18.
Status change: Active, Not Recruiting → Recruiting 2026-06-15
Trial Details
NCT Number NCT07074496
Lead Sponsor The First Affiliated Hospital of Soochow University
Collaborators: Fundamenta Therapeutics, Ltd.
Conditions Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Enrollment 20 participants
Start Date 2024-01-01
Primary Completion 2025-11-15 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-17